Cicatricial Alopecias and the Role of Janus Kinase Inhibitors: A Novel Approach and Comprehensive Overview to a Challenging Problem
DOI:
https://doi.org/10.58931/cdt.2025.62143Abstract
Cicatricial alopecias (CAs) represent a group of conditions that result in permanent hair loss due to the destruction of hair follicles and their replacement with scar tissue. Recently, Janus kinase (JAK) inhibitors have emerged as potential treatments for various alopecias, including scarring types. In this review, we will discuss CAs, their pathophysiology, diagnosis, and the evolving role of JAK inhibitors in their treatment.
References
Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol. 2001;19(2):211-225. https://doi.org/10.1016/s0738-081x(00)00132-2
Meyer KC, Tiede S, Harries MJ, Kloepper JE, Paus R. IFN-gamma induces bulge immunoprivilege collapse and may cause epithelial stem cell exhaust. J Invest Dermatol. 2010;130:S42-S42.
Moretti S, Amato L, Massi D, Bianchi B, Gallerani I, Fabbri P. Evaluation of inflammatory infiltrate and fibrogenic cytokines in pseudopelade of Brocq suggests the involvement of T-helper 2 and 3 cytokines. Br J Dermatol. 2004;151(1):84-90. doi:10.1111/j.1365-2133.2004.05976.x
Del Duca E, Ruano Ruiz J, Pavel A, Sanyal RD, Song T, Gay-Mimbrera J, et al. Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. Br J Dermatol. 2020;183(6):1083-1093. doi:10.1111/bjd.19040
Dubin C, Glickman JW, Del Duca E, Chennareddy S, Han J, Dahabreh D, et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022;86(3):551-562. doi:10.1016/j.jaad.2021.05.016
Chen LC, Ogbutor C, Kelley KJ, Senna MM. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024;90(6):1260-1262. doi:10.1016/j.jaad.2024.01.060
Desai D, Nohria A, Lo Sicco K, Shapiro J. The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: a case report. JAAD Case Rep. 2024;50:141–143. doi: 10.1016/j.jdcr.2024.04.034
Dunn C, Griffith V, Coican A, Dane A, Chow W, Aneja S, et al. Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: a case series and review of the literature. JAAD Case Rep. 2023; 40:47-52. doi:10.1016/j.jdcr.2023.07.037
Williams KN, Perez SM, Burroway B, Tosti A. Topical ruxolitinib in the management of frontal fibrosing alopecia and/or lichen planopilaris: a single-center retrospective cohort study. J Am Acad Dermatol. 2025;92(1):170-172. doi: 10.1016/j.jaad.2024.09.032.
David E, Shokrian N, Del Duca E, Meariman M, Dubin C, Hawkins K, et al. A phase 2a trial of brepocitinib for cicatricial alopecia. J Am Acad Dermatol. 2024 Oct 24:S0190-9622(24)03043-3. doi: 10.1016/j.jaad.2024.09.073.
